About: A review of equine sepsis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A review of equine sepsis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A review of equine sepsis
Creator	Taylor, S
Source	Medline; PMC
abstract	Sepsis is defined as an exaggerated, systemic inflammatory response to infection and is a common condition in horses. Systemic inflammatory response syndrome (SIRS) associated with bacterial infection is a hallmark of sepsis. Sepsis in neonatal foals is a common sequela of failure of passive transfer and, in addition to development of SIRS, may be characterised by bacteraemia, pneumonia, enterocolitis, omphalophlebitis, meningoencephalitis or arthritis. Sepsis in mature horses is most commonly observed secondary to gastrointestinal lesions that result in disrupted mucosa and bacterial translocation into circulation (endotoxaemia). Pleuropneumonia and metritis may also cause sepsis in mature horses. Diagnosis of sepsis is based on SIRS criteria as well as suspected or confirmed infection. Due to the relatively low sensitivity of microbial culture and the subjectivity of sepsis scoring, many sepsis biomarkers are being studied for their usefulness in diagnosis and prognostication of sepsis in horses. Treatment of sepsis requires an intensive care approach that includes antimicrobial drug administration, fluid resuscitation and pressure support, and treatment for inflammation, endotoxaemia and coagulopathy. Early recognition of sepsis and prompt antimicrobial drug treatment are critical for a successful outcome. Multiple organ dysfunction syndrome may occur in severe cases of sepsis, with common manifestations including laminitis and coagulopathies. Although prognosis for septic mature horses depends highly on the primary disease process, the overall survival rate in septic neonatal foals ranges from 26 to 86%, with most studies indicating a survival rate of 45–60%.
has issue date	2015-01-14(xsd:dateTime)
bibo:doi	10.1111/eve.12290
bibo:pmid	32313390
has license	no-cc
sha1sum (hex)	ce0a5bd747cbf5f982d2f0483e7969522a5b034a
schema:url	https://doi.org/10.1111/eve.12290
resource representing a document's title	A review of equine sepsis
has PubMed Central identifier	PMC7163761
has PubMed identifier	32313390
schema:publication	Equine Vet Educ
resource representing a document's body	covid:ce0a5bd747cbf5f982d2f0483e7969522a5b034a#body_text
is schema:about of	named entity 'Although' named entity 'enterocolitis' named entity 'pneumonia' named entity 'coagulopathies' named entity 'scoring' named entity 'sepsis' named entity 'common' named entity 'sepsis' named entity 'SCORING' named entity 'OCCUR' named entity 'survival rate' named entity 'mature' named entity 'fluid resuscitation' named entity 'gastrointestinal' named entity 'microbial culture' named entity 'studied' named entity 'process' named entity 'Pleuropneumonia' named entity 'observed' named entity 'Sepsis' named entity 'inflammation' named entity 'Due' named entity 'pneumonia' named entity 'laminitis' named entity 'passive transfer' named entity 'bacterial infection' named entity 'Systemic inflammatory response syndrome' named entity 'sepsis' named entity 'SIRS' named entity 'Pseudomonas aeruginosa' named entity 'corticosteroid' named entity 'anti-inflammatory' named entity 'sepsis' named entity 'MD2' named entity 'gene expression' named entity 'clinical cases' named entity 'C-reactive protein' named entity 'LPS' named entity 'sepsis' named entity 'Targeted therapy' named entity 'SAA' named entity 'LPS' named entity 'equine' named entity 'heart rate' named entity 'band neutrophils' named entity 'Prophylactic treatment' named entity 'biomarkers' named entity 'long-term' named entity 'IL8' named entity 'Haematogenous' named entity 'electrolyte' named entity 'sepsis' named entity 'septic arthritis' named entity 'equine studies' named entity 'polymyxin' named entity 'critically ill' named entity 'meningoencephalitis' named entity 'Anaerobic' named entity 'gastric ulceration' named entity 'septic shock' named entity 'sepsis' named entity 'bacteraemia' named entity 'Idexx Laboratories' named entity 'equine' named entity 'bacterial translocation' named entity 'cytology' named entity 'anti-ulcer' named entity 'mmol/l' named entity 'hypothermia' named entity 'electrolyte' named entity 'positively correlated' named entity 'fluoroquinolones' named entity 'LPS' named entity 'aminoglycoside' named entity 'Sepsis' named entity 'Thoroughbred' named entity 'kidney disease' named entity 'bacteraemia' named entity 'Viu' named entity 'infectious agents' named entity 'anticoagulant'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software